Please log in to see the full text of this API!
Ado-Trastuzumab Emtansine
-
Synonyms:
Trastuzumab emtansine; T-DM1
-
ATC:
L01XC14
-
Use:
Lorem
-
Chemical name:
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam
-
Formula:
Lorem ipsum dolor sit amet,
-
MW:148.5 kDa
-
CAS-RN:1018448-65-1
Substances Referenced in Synthesis Path
| CAS-RN |
Formula |
Chemical Name |
CAS Index Name |
| 860706-16-7 |
C3H6O2S |
3-mercaptopropanoic acid |
|
| 138148-59-1 |
C4H8O2S2 |
3-(methyldithio)-propanoic acid |
|
| 6066-82-6 |
C4H5NO3 |
N-hydroxy-succinimide |
|
| 3913-67-5 |
C4H9NO2 |
N-methyl-L-alanine |
|
| Lorem |
Lorem |
Lorem |
Lorem |
| Lorem |
Lorem |
Lorem |
Lorem |
| Lorem |
Lorem |
Lorem |
Lorem |
Trade Names
| Country |
Trade Name |
Vendor |
Annotation |
| EU |
Lorem |
Lorem
|
|
| USA |
Lorem |
Lorem
|
|
(wfm = withdrawn from market)
Formulations
- Loremipsumdolorsitamet,consetetursadipscingelitr,seddiamnonumyeirmodtemporinviduntut
References
-
- Chari, R. J. V. et al.,''Antibody-Drug Conjugate: An Emerging Concept in Cancer Therap.'', Angew. Chem. Int. Ed., (2014) 53(15), 3796-3827.
- Lambert, J. M.; Chari, R. J. V., ''Ado-Trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer'', J. Med. Chem., (2014) 57(15), 3796-3827.
- US 9 999 999 (Immunogen Inc.; 22.10.2013; USA-prior. 08.10.2003; 29.10.2007).
- US 9 999 999 (Immunogen Inc.; 07.01.2014; USA-prior. 03.06.2009; 03.06.2010).
- US 9 999 999 (Immunogen Inc.; 01.04.2014; USA-prior. 10.10.2003; 08.10.2004; 29.10.2007).
-
Analogs and intermediates:
- Widdison, W. C. et al., J. Med. Chem., (2006) 49, 4392-4408.
-
Trastuzumab (Herceptin):
- US 9 999 999 (Genentech; 13.10.1998; USA-prior. 14.06.1991; 15.06.1992; 21.08.1992).
-
DM1:
- US 9 999 999 (Immunogen Inc.; 04.05.1993; USA-prior. 25.10.1989; 13.07.1992).
- US 9 999 999 (Immunogen Inc.; 25.12.2001; USA-prior. 18.08.2000).
-
Ansamitocins by fermentation:
- US 9 999 999 (Takeda; 24.04.1979; JP-prior. 01.04.1977; 31.03.1977).
